FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes.

Although the rate of perinatal HIV infection is low, more than 50% of HIV infections in infants before age 1 year occurred in those who did not receive postnatal prophylaxis.

Routine tests in the third trimester may catch missed cases and flag the need for treatment that reduces a baby‘s risk of getting HIV to near zero.

This raises the possibility that preventive strategies should vary based on the type of mitral surgery, but more research is ...

Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk ...

Pemivibart was well tolerated and prophylactic against COVID-19 infection among adult patients with significant immunocompromising conditions.

Moderate US Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia.

Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

Gilead (GILD) wins the backing of an EU panel for lenacapavir, its twice-yearly injectable for prevention of HIV in ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Over 5 years of treatment in hemophilia B patients, gene therapy research shows sustained factor IX activity and safety.

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and ...